KNDL

Pharma

Kendle acquired by INC Research in $232 million CRO deal

Cincinnati-based contract research organization Kendle International (Nasdaq:KNDL) has solved its “acquire-or-be-acquired” dilemma. Kendle agreed to sell itself to Raleigh, North Carolina-based CRO INC Research for $232 million, according to a statement from the companies. The selling price of $15.25 per share represents a 60.5 percent premium over Kendle’s closing share price on Wednesday. Kendle’s board […]

Pharma

Growing CRO demand boosts outlook for Kendle

A strange thing happened on Kendle International‘s (NASDAQ:KNDL) most recent quarterly earnings conference call. An analyst asked CEO-to-be Steve Cutler if he planned to make any significant changes once he takes the company’s reins from current CEO and founder Candace Kendle. Bearing in mind that Kendle had just announced a $9 million loss — its […]

sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.